K
Keynote Investigators
Publications - 8
Citations - 6369
Keynote Investigators is an academic researcher. The author has contributed to research in topics: Pembrolizumab & Lung cancer. The author has an hindex of 7, co-authored 8 publications receiving 2451 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz-Ares,Alexander Luft,David Vicente,Ali Tafreshi,Mahmut Gumus,Julien Mazieres,Barbara Hermes,Filiz Çay Şenler,Tibor Csőszi,Andrea Fülöp,Jerónimo Rodríguez-Cid,Jonathan Wilson,Shunichi Sugawara,Terufumi Kato,Ki Hyeong Lee,Ying Cheng,Silvia Novello,Balazs Halmos,Xiaodong Li,Gregory M. Lubiniecki,Bilal Piperdi,Dariusz M. Kowalski,Keynote Investigators +22 more
TL;DR: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus pac litaxel or nab‐paclitaxel resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid,Javier Cortes,Lajos Pusztai,Heather L. McArthur,Sherko Kümmel,Jonas Bergh,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Theodoros Foukakis,Peter A. Fasching,Fatima Cardoso,Michael Untch,L. Jia,Vassiliki Karantza,Jing Zhao,Gursel Aktan,Rebecca Dent,Joyce O'Shaughnessy,Keynote Investigators +21 more
TL;DR: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among thosewho received placebo plusNeoadjuant chemotherapy.
Journal ArticleDOI
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
Thierry André,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J. A. Punt,Denis Smith,Rocio Garcia-Carbonero,Manuel Benavides,Peter Gibbs,Christelle De La Fouchardiere,Fernando Rivera,Elena Elez,Johanna C. Bendell,Dung T. Le,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Patricia Marinello,Luis A. Diaz,Keynote Investigators +21 more
TL;DR: Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events.
Journal ArticleDOI
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
Takashi Kojima,Manish A. Shah,Kei Muro,Eric Francois,Antoine Adenis,Chih-Hung Hsu,Toshihiko Doi,Toshikazu Moriwaki,Sung Bae Kim,Se-Hoon Lee,Jaafar Bennouna,Ken Kato,Lin Shen,Peter C. Enzinger,Shukui Qin,Paula Ferreira,Jia Chen,Gustavo Girotto,Christelle De La Fouchardiere,Hélène Senellart,Raed Al-Rajabi,Florian Lordick,Ruixue Wang,Shailaja Suryawanshi,Pooja Bhagia,S. Peter Kang,Jean-Philippe Metges,Keynote Investigators +27 more
TL;DR: Pembrolizumab prolonged OS versus chemotherapy as second-line therapy for advanced esophageal cancer in patients with programmed death ligand-1 combined positive score (CPS) ≥ 10, with fewer treatment-related adverse events.
Journal ArticleDOI
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong-Mu Sun,Lin Shen,Manish A. Shah,Peter C. Enzinger,Antoine Adenis,Toshihiko Doi,Takashi Kojima,Jean-Philippe Metges,Zhigang Li,Sung Bae Kim,Byoung Chul Cho,Wasat Mansoor,Shau-Hsuan Li,Patrapim Sunpaweravong,Maria Alsina Maqueda,Eray Goekkurt,Hiroki Hara,Luis Carlos Moreira Antunes,Christos Fountzilas,Akihito Tsuji,Victor Castro Oliden,Qi Liu,Sukrut Shah,Pooja Bhagia,Ken Kato,Keynote Investigators +25 more
TL;DR: In this paper, the authors compared pembrolizumab plus chemotherapy versus chemotherapy alone as a first-line treatment for advanced oesophageal cancer and Siewert type 1 gastro-oesophagesphageal junction cancer.